Epidermal growth factor receptor (EGFR) is mutated, dysregulated or overexpressed in many epithelial malignancies, and EGFR activation has been found to be important in tumor growth and progression. Anti-EGFR monoclonal antibodies target the extracellular domain of EGFR; and show promising anti-tumor potential at clinical trials without severe side effects. In this article the pharmacokenetics and clinical study of 3 anti-EGFR monoclonal antibodies (cetuximab, panitumumab and nimotuzomab) were reviewed.
[Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review.] Publishing Authors By Initials
[Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review.] Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Zhongguo shi yan xue ye xue za zhi / Zhongguo bing
VOLUME: 15
Page Numbers: 1135-8
Journal Abbreviation: Zhongguo Shi Yan Xue Ye Xue Za
ISSN: 1009-2137
DAY: 24
MONTH: Oct
YEAR: 2007
[Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review.] Information
Number of References:
LANGUAGE: chi
NlmUniqueID: 101084424
[Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review.] Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: [Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review.] Information
Substance Name:
Registry Number:
Grant and Affiliation Information for [Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review.]
AFFILIATION: Key Laboratory of Pharmacokinetics, Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China; Department of Pharmacology, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Country: China
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Zhongguo Shi Yan Xue Ye Xue Za
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Biotherapy of Cancer by Anti-EGFR Monoclonal Antibody - Review Related Publications